[Use of antiseptic myramistin in the multimodality treatment of nonspecific suppurative pleuropulmonary diseases].
To treat patients with suppurative diseases of the bronchi, lung, and pleura, the new aseptic myramistine was topically applied as 0.005% myramistine solution in isotonic sodium chloride solution in 28 patients with acute and chronic pleural empyema, acute abscess of the lung, and suppurative endobronchitis-complicated bronchoectatic disease. The therapy made it possible to arrest the intoxication syndrome, to achieve abacillation of contents in the cavities of empyema, abscesses, and bronchoectases, to cure endobronchitis, to obliterate destructive cavities in the lung more rapidly and to prepare patients for a planned surgical intervention more valuably and to improve the results of surgical treatment. The studies allow the antiseptic myramistine to be recommended for topical treatment of pyodestructive diseases of the lung.
Grishin
M N
MN
D000287:Administration, Topical; D000328:Adult; D000891:Anti-Infective Agents, Local / Q000008:administration & dosage / Q000627:therapeutic use*; D001548:Benzalkonium Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D001987:Bronchiectasis / Q000188:drug therapy*; D001999:Bronchoscopy; D016724:Empyema, Pleural / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008169:Lung Abscess / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D019152:Paracentesis; D013492:Suppuration / Q000188:drug therapy; D007507:Therapeutic Irrigation; D016896:Treatment Outcome
D000891:Anti-Infective Agents, Local; D001548:Benzalkonium Compounds; C058048:miramistin